PHILADELPHIA, July 9, 2026
Century Therapeutics announced that its CNTY-813 preclinical research has been selected for oral presentations at two leading international scientific conferences, the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, and the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia. The company will present new findings highlighting the scalable manufacturing and preclinical performance of CNTY-813, its investigational induced pluripotent stem cell (iPSC)-derived islet replacement therapy engineered with the proprietary Allo-Evasion™ 5.0 technology for patients with Type 1 Diabetes (T1D). The dual oral presentations underscore growing scientific recognition of Century Therapeutics’ innovative approach to developing off-the-shelf regenerative cell therapies designed to overcome immune rejection while expanding treatment accessibility for people living with autoimmune diseases.
CNTY-813 Demonstrates Scalable Manufacturing and Immune Evasion Technology
Century Therapeutics will present research demonstrating the scalable production of Allo-Evasion™ 5.0-engineered iPSC-derived beta islets, a key advancement in manufacturing next-generation cell therapies for diabetes. CNTY-813 has been specifically designed to replace insulin-producing pancreatic islet cells destroyed by autoimmune attack in Type 1 Diabetes. The company’s proprietary Allo-Evasion™ 5.0 platform is intended to protect transplanted cells from immune-mediated rejection, potentially eliminating the need for chronic systemic immunosuppressive therapy, one of the major limitations associated with currently approved and late-stage islet cell replacement therapies. The presentations will highlight reproducible manufacturing processes that support large-scale production of standardized off-the-shelf cell therapy products, representing an important milestone toward broader clinical availability.
Preclinical Results Support Future Clinical Development in Type 1 Diabetes
According to the company, preclinical studies have demonstrated that CNTY-813 exhibits robust glucose-responsive insulin function, a favorable preclinical safety profile, scalable manufacturing capability, and durable immune protection under alloimmune pressure. These findings suggest that the engineered islet cells may provide long-term functional insulin production while resisting immune destruction after transplantation. The technology combines iPSC-derived regenerative medicine with sophisticated immune engineering, creating a potential therapeutic approach that addresses both the replacement of damaged beta cells and the immune barriers that have historically limited long-term success in cell-based diabetes therapies. The oral presentations at both scientific meetings are expected to provide researchers and clinicians with additional insight into the translational potential of this novel therapeutic platform.
Advertisement
Century Therapeutics Targets IND Submission for CNTY-813 in Late 2026
The upcoming scientific presentations represent another important step in the continued advancement of Century Therapeutics’ autoimmune disease pipeline. The company is currently targeting an Investigational New Drug (IND) submission during the fourth quarter of 2026, moving CNTY-813 closer to clinical evaluation in patients with Type 1 Diabetes. Century Therapeutics continues to leverage its proprietary iPSC cell foundry and Allo-Evasion™ platform to develop next-generation off-the-shelf cell therapies for autoimmune diseases and cancer. By combining scalable manufacturing, immune evasion technology, and regenerative medicine, the company aims to expand patient access to advanced cell therapies while addressing critical unmet medical needs. Selection for oral presentations at two prestigious international scientific meetings further validates the growing interest in CNTY-813 and reinforces Century Therapeutics’ position as an emerging innovator in regenerative medicine and diabetes cell therapy development.
Source: Century Therapeutics press release
